Novel bispecific antibodies increase gd t-cell cytotoxicity against pancreatic cancer cells

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1349-1360

  Oberg, Hans Heinrich ^a   Peipp, Matthias ^b   Kellner, Christian ^b   Sebens, Susanne ^c   Krause, Sarah ^a   Petrick, Domantas ^a   Adam Klages, Sabine ^a   Rocken, Christoph ^d   Becker, Thomas ^e   Vogel, Ilka ^f   Weisner, Dietrich ^g   Freitag Wolf, Sandra ^a   Gramatzki, Martin ^b   Kabelitz, Dieter ^a   Wesch, Daniela ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Division of Stem Cell Transplantation and Immunotherapy   (United States)

^c Institute for Experimental Medicine   (Czech Republic)

^d Institute of Pathology   (Czech Republic)

^e Clinic of General and Thoracic Surgery   (United States)

^f Municipal Hospital Department of Surgery   (United States)

^g Treatment Centre for Gynaecology and Obstetrics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANZYME B; PERFORIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME RELEASE; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; MICE; MICE, SCID; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84896524478     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0675     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi B, Pintilie M, et al. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS ONE 2012;7: e46677.
3. Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81:126-34.
4. Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 2012;23:570-6.
5. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
6. Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, et al. Human gd T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 2012;188:1708-16.
7. Braza MS, Klein B. Anti-Tumour immunotherapy with Vg9Vd2 T lymphocytes: from the bench to the bedside. Br J Haematol 2013;160: 123-32.
8. Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F, et al. What lessons can be learned from gd T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013;10:35-41.
9. Bouet-Toussaint F, Cabillic F, Toutirais O, Le GM, Thomas dlP, Daniel P, et al. Vg9Vd2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 2008;57:531-9.
10. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7.
11. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-Tumor effects of adoptive immunotherapy using gd T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469-76.
12. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vg9Vd2 T cells with zoledronate and lowdose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010;161:290-7.
13. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gd T cell activation induced by zoledronic acid through accumulation of IPP/ DMAPP. Br J Haematol 2009;144:245-50.
14. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagne F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gd T cells. J Biol Chem 2001;276: 18337-44.
15. Kabelitz D, Wesch D, Pitters E, Z̈oller M. Characterization of tumor reactivity of human Vg9Vd2 gd T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-76.
16. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, et al. Tumor-promoting versus tumor-Antagonizing roles of gd T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 2012;35:205-13.
17. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 2008;321:974-7.
18. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012;136:334-42.
19. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119: 6226-33.
20. Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106:1033-8.
21. Novotny J, Petruzelka L, Vedralova J, Kleibl Z, Matous B, Juda L. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma 2001;48:188-91.
22. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006;7: 283-94.
23. Safran H, Steinhoff M, Mangray S, Rathore R, King TC, Chai L, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001;24:496-9.
24. Hofmeister R, Kohleisen B, Lenkeri-Schuetz U, Itin C, Baeuerle PA, Carr FJ, et al. inventors; Multispecific deimmunized CD3 binders. WO2005/040220 2005.
25. Fey GH, Peipp M, Schwemmlein M, inventors; CD19-specific immuntoxin and treatment method. WO2007/085470 2007.
26. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, et al. Combined Fc-protein-And Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 2011; 373:67-78.
27. Derer S, Kellner C, Berger S, Valerius T, Peipp M. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. Methods Mol Biol 2012;907: 519-36.
28. Janssen O, Wesselborg S, Heckl-Ostreicher B, Pechhold K, Bender A, Schondelmaier S, et al. T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gd+ T cells. J Immunol 1991;146: 35-9.
29. Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, et al. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia 2013;27:190-201.
30. Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 2004;125:167-79.
31. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gd T cells. Cancer Res 2009;69:8710-7.
32. Capietto AH, Martinet L, Fournie JJ. Stimulated gd T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol 2011;187:1031-8.
33. Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G, et al. Optimizing tumor-reactive gd T cells for antibody-based cancer immunotherapy. Curr Mol Med 2010;10:719-26.
34. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009;11:22-30.
35. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43: 1129-43.
36. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012;188:1551-8.
37. Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011;303:128-39.
38. Roder C, Trauzold A, Kalthoff H. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol 2011;90:450-5.
39. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 2009; 124:853-61.
40. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A. Chemokine receptors expression and migration potential of tumorinfiltrating and peripheral-expanded Vg9Vd2 T cells from renal cell carcinoma patients. J Immunother 2008;31:313-23.
41. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood gd T lymphocytes: strong expression of CCR5 is a selective feature of Vd2/ Vg9 gd T cells. J Immunol 2002;168:4920-9.
42. Capietto AH, Martinet L, Fournie JJ. How tumors might withstand gd Tcell attack. Cell Mol Life Sci 2011;68:2433-42.
43. Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012;3: 270.
44. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012;33: 119-26.
45. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2009;39:797-806.
46. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.
47. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vg9Vd2 T cell cytotoxicity. Cancer Immunol Immunother 2007;56:1285-97.
48. Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol 2011;2011: 161862.
49. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011;8:27-33.
50. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by gd T lymphocytes. J Immunol 2009;182:7287-96.